us regul rule pain drugus food drug regul will decid friday whether recommend sale painkil link high risk heart attack strokefood drug administr fda advisori panel will give verdict hear evid three day painkil  call cox2 inhibitor  sold brand name celebrex vioxx vioxx withdrawn shop last year merck said consid sell get fda approv fda ask decid benefit patient justifi increas riskput vioxx back shelv like boost profit merck make easier legal battl peopl claim injur drug analyst saidmerck voluntarili stop sale vioxx 30 septemb move caus firm fourthquart earn slide 11bn 581m 14bn year earlier merck share tumbl 10 news compani set asid million dollar cover cost vioxxrel litig alarm bell rung research note call approv show risk heart attack stroke doubl patient take drug least 18 month cox2 inhibitor develop drug compani includ merck pfizer caus user fewer stomach problem painkilpfizer still sell celebrex bextra product though investig suggest may also harm heart merck announc possibl reintroduct vioxx caught analyst surpris merck head research peter kim said withdrew vioxx base inform avail us time know altern therapi went say thing sinc chang light new report given new inform clear cardiovascular risk observ approv make vioxx uniqu class similar drug market us mr kim explainthursday david graham fdas offic drug safeti told advisori panel realli appear need cox2 inhibitor accord calcul present us senat dr graham novemb vioxx may link mani 56000 american death face stem critic handl vioxx case fda said tuesday will creat independ bodi overse safeti drug alreadi market place european regul meanwhil rule thursday patient heart diseas stroke take cox2 inhibitor european medicin agenc also said doctor cautious give drug patient risk factor heart diseas